Tie-ing the Antiinflammatory Effect of Angiopoietin-1 to Inhibition of NF-κB

Byeong Hwa Jeon, Firdous Khanday, Shailesh Deshpande, Azeb Haile, Michitaka Ozaki, Kaikobad Irani

Activation of the vascular endothelium occurs in many clinical scenarios such as inflammatory or infectious conditions (sepsis), reperfusion injury, and transplant graft rejection.1–5 Under such circumstances, endothelial activation is primarily induced by cytokines such as tumor necrosis factor (TNF) and interleukin-1β (IL-1β) and vascular permeability factors such as vascular endothelial growth factor (VEGF) that upregulate a number of genes including prothrombotic factors, chemokines, and cell adhesion molecules, many of which are dependent on the action of the pleiotropic transcription factor nuclear factorκB (NFκB).2,6–11 Activated endothelium is compromised in its structural and functional integrity, leading to transmigration of leukocytes into the vessel wall, plasma leakage, and thrombosis.

Angiopoietin-1 (Ang1) is a vasculogenic factor that induces endothelial cell sprouting, migration, and network formation,12–15 coordinated processes that are crucial in the development of new blood vessels. Angiopoietins signal via the Tie (tyrosine kinase with immunoglobulin and epidermal growth factor homology domains) family of receptor tyrosine kinases, of which Tie2 is endothelial-cell specific. In addition to its important role in vasculogenesis, Ang1, through Tie2, suppresses activation of endothelial cells as evidenced by its inhibition of vascular cell adhesion molecules and procoagulant tissue factor expression.16,17 These effects confer on Ang1 potent antiflammatory properties.18–20 Although Ang1 affects the expression of many NFκB–responsive genes, a functional and mechanistic link between Ang1 and NFκB signaling has not been previously shown.

The report by Hughes et al21 in this issue of Circulation Research provides the first demonstration that the mitigating effect of Ang1 on endothelial cell activation may be because of binding of its activated Tie2 receptor to a protein previously shown to modulate NFκB activation. Using a yeast two-hybrid screen with the intracellular domain of Tie2 as the bait and a human endothelial cell cDNA library, the authors isolate a cDNA clone that turns out to code for a protein termed ABIN-2 (A20 binding inhibitor of NFκB activation-2) and show that ABIN-2 also associates with full-length Tie2 in mammalian cells. By demonstrating that ABIN-2-Tie2 association is dependent on phosphorylation of Tie2 (an early event that occurs with binding to Ang1), and that Ang1 stimulates this association in endothelial cells, the authors provide a convincing case for the physiological relevance of this association. Moreover, using a deletion mutant of ABIN-2 that would be expected to interact with Tie2 but does not have the capacity to inhibit NFκB22 (and can therefore be presumed to act in a dominant inhibitory fashion with respect to Tie2-ABIN-2 interaction), the authors show that this interaction may have functional relevance in the context of Ang1’s effect on phorbol ester–stimulated NFκB activity. Interestingly, outside of the context of Ang1 inhibition of NFκB activation, and contrary to prior reports,22 expression of this mutant augments phorbol ester–stimulated κB activity.

As the name implies, the murine homologue of ABIN-2 was first identified as a protein that interacts with A20, a well-known inhibitor of NFκB activation.22 A20, a zinc finger protein, was itself first cloned from endothelial cells as an early-response gene induced by TNF,23 and whose expression is controlled by NFκB,24 thus acting as a negative modulator of NFκB activation. ABIN-2 functions in a similar capacity by inhibiting NFκB activation in response to a variety of stimuli (TNF, IL-1, phorbol esters), exacting its effect at a point in the activation cascade identical to that of A20.22 However, unlike A20, ABIN-2 is constitutively expressed in both murine and human tissues.21,22 The finding by Hughes et al21 that ABIN-2 structurally and functionally interacts with Ang1-Tie2 signaling also implicates, although does not prove, a role for A20 in Ang1-induced suppression of stimulated NFκB activity as well. Speaking against this possibility is the recent report that ABIN-1 (that also binds to A20 through a conserved domain shared with ABIN-222) does not require A20 to suppress NFκB activity.25

Part of the intrigue created by the findings reported by Hughes et al21 is that ABIN-2 was identified only very recently, and there is a dearth of information about the mechanism(s) by which it inhibits NFκB. ABIN-2 does not have classic phosphotyrosine-binding domains (such as src homology domain 2 [SH2]) that are necessary for interaction of other proteins (Grb adaptors and p85 subunit of phosphatidylinositol 3-kinase [PI3K]) to tyrosine-phosphorylated Tie2. The residues on Tie2 and ABIN-2 that are critical for their interaction, and how such an interaction cross-communicates with the NFκB signaling machinery, to modulate NFκB activation, remain to be identified, and will surely spur intense investigation in the years to come. Regarding the
Ang-1–Tie2 signaling in endothelial cells. Proposed model showing known (solid line) and potential (dashed line) signaling pathways activated or inhibited by Ang1–Tie2, and proteins known to interact with phosphorylated Tie2, with the specific residues, when known, indicated. The exact nature of, and residues involved in, the Tie2–ABIN-2 interaction is not known. Only one hypothetical mechanism by which ABIN-2 may inhibit NF-κB activation is shown. (Other potential mechanisms, such as via A20, are not shown.) Note: VEGF can also lead to endothelial cell survival, migration, and promote angiogenesis. Ang1 indicates angiopoietin-1; Y, tyrosine residue; Shp-2, protein tyrosine phosphatase; p85, regulatory subunit of PI3K; p110, catalytic subunit of PI3K; Grb, adaptor proteins; STAT, signal transducer and activator of transcription; FAK, focal adhesion kinase; and PAK, p21-activated kinase.

In summary, the data offered by Hughes et al\textsuperscript{21} show that the Tie2-ABIN-2 interaction is responsible for the inhibitory effects of Ang1 on stimulated NF-κB activity, implicating this novel interaction in mediating the antiinflammatory properties of Ang1. However, in addition to its role in inflammation, NF-κB has myriad effects, raising numerous questions as to how, if at all, the Tie2-ABIN-2 interaction modulates the other effects of Ang1 on endothelial cells (Figure). For example, what role, if any, does ABIN-2 play in Ang1-stimulated endothelial cell survival\textsuperscript{26} and migration,\textsuperscript{15} both of which are critical in angiogenesis, and both of which in endothelial cells or other cellular systems involve NF-κB signaling in some fashion.\textsuperscript{27–29} Similar questions arise about the role of the Tie2-ABIN-2 interaction in molecular crosstalk with signaling pathways, such as PI3K-Akt, known to be activated by Ang1 (Figure), but that also modulate NF-κB activity.\textsuperscript{30} The answers to such questions will be crucial in determining the physiological relevance of the Tie2-ABIN-2 interaction and may provide important clues to the intricate process of blood vessel formation in normal physiology and disease states.

References


Key Words: angiopoietin-1 • Tie2 • nuclear factor-κB • endothelial cells • ABIN-2
Tie-ing the Antiinflammatory Effect of Angiopoietin-1 to Inhibition of NF-κB
Byeong Hwa Jeon, Firdous Khanday, Shailesh Deshpande, Azeb Haile, Michitaka Ozaki and Kaikobad Irani

Circ Res. 2003;92:586-588
doi: 10.1161/01.RES.0000066881.04116.45
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/92/6/586

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/